Buy oversold dips in Applied Optoelectronics (AAOI) following its recent capital raise, targeting a mean-reversion rebound toward the $115 to $118 range.

Establish a high-conviction speculative long position in Spruce Biosciences (SPRB), which offers 5x to 10x upside toward a $500 target as the market catches up to its rare disease drug pipeline.

Accumulate long-term exposure to the silicon photonics and optical components theme via data center suppliers Lumentum (LITE), Credo (CRDO), Fabrinet (FN), and Coherent (COHR) to ride AI infrastructure expansion.

Avoid long positions in Moderna (MRNA) and instead use temporary price rallies as short-selling opportunities given ongoing declines in vaccine demand.

Consider a tactical short-term dip buy on SanDisk around the $1,450–$1,460 level to capture an oversold bounce, keeping strict stop-losses in place to protect against broader semiconductor downturns.

Applied Optoelectronics (AAOI)

• The stock fell sharply (10% to 18%) following an ATM (at-the-market) share offering announcement.
• The sell-off is viewed as an overreaction by retail traders, as capital raises are currently common across tech and AI infrastructure.
• High-beta asset that presents a potential mean-reversion trade, with expectations for a recovery toward the $115 to $118 range.

Takeaways

• Consider buying oversold dips caused by standard capital raises, but manage risk carefully due to the stock's high volatility (beta).

Capricor Therapeutics (CAPR)

• The company received a three-month extension on its BLA (Biologics License Application) review period.
• The extension is viewed as a negative sign that merely delays an inevitable regulatory rejection rather than improving approval odds.
• Successfully traded as a short-side fade at the market open, covering the position near $6.

Takeaways

• Treat regulatory delays and extended review timelines with skepticism, using initial spikes as potential shorting opportunities.

Spruce Biosciences (SPRB)

• Positive developments in the pipeline have not yet been fully reflected in the market valuation.
• High conviction in the company's rare/orphan drug focus, with long-term upside potential projected between 5x to 10x (with a target mention of $500).
• Biotech markets often lag in recognizing orphan drug asset value, requiring patience through low sentiment periods.

Takeaways

• Long-term speculative buy for investors willing to endure biotech volatility for substantial upside in orphan drug pipelines.

SanDisk

• The stock experienced a sharp pullback of over 10%, dropping toward the $1,450–$1,460 level.
• Taken as a tactical dip-buy opportunity to capture an oversold bounce driven by macro yield concerns.
• Diverging views were noted, with short-sellers targeting a fall into the triple digits (sub-$1,000) if the broader semiconductor cycle cools down.

Takeaways

• Short-term opportunity to buy heavy pullbacks for mean-reversion bounces, while setting strict stop-losses against a broader cyclical downturn.

Moderna (MRNA)

• Covered a large, profitable short position after a continued slide.
• Continued negative sentiment surrounding the core franchise and vaccine demand.
• Outlook remains bearish, with expectations that the stock will continue to bleed value over the medium term.

Takeaways

• Avoid long exposure; look for tactical short opportunities on temporary rallies.

Advanced Micro Devices (AMD)

• Skepticism expressed regarding the company's ability to compete effectively in the high-end GPU market against entrenched leaders.
• While the company remains viable in the traditional CPU market, valuation is questionable without clear GPU leadership.

Takeaways

• Exercise caution before buying AMD purely as an AI/GPU play until there is stronger proof of competitive execution.

Psychedelic Biopharmaceutical Sector (DFTX / GHRS)

• Clinical trial data for psychedelics in psychiatric conditions is showing significant efficacy over traditional SSRIs.
• DFTX is advancing Phase 3 clinical data using pharmaceutical-grade LSD for generalized anxiety disorder.
• GHRS is developing DMT-based therapies for treatment-resistant depression with promising clinical upside.

Takeaways

• Monitor clinical-stage psychedelic biotechs with robust Phase 2/3 data as emerging alternatives in mental health therapeutics.

Optical & Silicon Photonics Sector (LITE, CRDO, FN, COHR, QCLS)

• Silicon photonics is an emerging secular theme that leverages existing semiconductor infrastructure to build optical chips.
• Transceiver and optical component demand is expanding due to data center compute requirements.
• Key suppliers and players in this theme include Lumentum (LITE), Credo (CRDO), Fabrinet (FN), and Coherent (COHR).

Takeaways

• Build long-term exposure to optical component and silicon photonics leaders benefiting from the ongoing AI infrastructure expansion.

Solana Meme Tokens (Pump.fun Ecosystem)

• Ultra-short-term momentum trading characterized by extreme volatility and severe liquidity constraints.
• Positions are vulnerable to instant "rug pulls," high slippage, and front-running bots.
• Trades require immediate execution (holding times measured in seconds or minutes) with strict profit-taking.

Takeaways

• Treat micro-cap meme tokens as pure high-risk gambling; never commit core capital, avoid averaging down, and take profits rapidly.